Zylet Bausch & Lomb - Treatment for Inflammatory Ocular Conditions
Zylet is a corticosteroid and antibiotic combination for the treatment of steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of infection exists. Zylet will be available in the United States early in the first quarter of 2005.Posted: December 2004
Related articles
- FDA Issues Approvable Letter to Bausch & Lomb for Ophthalmic Anti-inflammatory/Antibiotic Combination Product - August 9, 2004
Zylet (loteprednol and tobramycin) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
